The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world’s first and only medical device that can monitor and respond to brain activity.

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company’s initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.

In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.

Type
Private
HQ
Mountain View, US
Founded
1999
Size (employees)
145 (est)+2%
NeuroPace was founded in 1999 and is headquartered in Mountain View, US
Report incorrect company information

Key People/Management at NeuroPace

Frank Fischer

Frank Fischer

Chief Executive Officer, Board Member
Rebecca Kuhn

Rebecca Kuhn

Chief Financial Officer, Vice President, Finance & Administration
Martha Morrell

Martha Morrell

Chief Medical Officer
Isabella Abati

Isabella Abati

Vice President, Regulatory Affairs
Andre Marquette

Andre Marquette

Chief Commercial Officer
Show more

NeuroPace Office Locations

NeuroPace has an office in Mountain View
Mountain View, US (HQ)
455 N Bernardo Ave
Show all (1)
Report incorrect company information

NeuroPace Financials and Metrics

Summary Metrics

Founding Date

1999

NeuroPace total Funding

$141 m

NeuroPace latest funding size

$74 m

Time since last funding

9 months ago

NeuroPace investors

NeuroPace's latest funding round in October 2017 was reported to be $74 m. In total, NeuroPace has raised $141 m
Show all financial metrics
Report incorrect company information

NeuroPace Online and Social Media Presence

Embed Graph
Report incorrect company information

NeuroPace News and Updates

NeuroPace raises $74 million to market seizure-monitoring device: Reuters

NeuroPace Inc said on Tuesday it raised $74 million in equity funding as the medical device maker looks to rapidly expand commercialization of its device to treat epileptic seizures.
Report incorrect company information

NeuroPace Company Life and Culture

Report incorrect company information